Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions Inc (NASDAQ: BLFS) maintains industry leadership through innovative biopreservation solutions for cell and gene therapies. This dedicated news hub provides comprehensive updates on corporate developments, regulatory milestones, and technological advancements essential for stakeholders in the life sciences sector.
Access official press releases covering quarterly earnings, strategic partnerships, and product innovations in cryopreservation media and cold chain management systems. Our curated collection serves investors and researchers requiring timely, accurate information about BLFS's role in advancing biologic manufacturing infrastructure.
The resource prioritizes updates on BioLife's core competencies: clinical-grade cell processing tools, smart shipper technologies, and quality assurance protocols critical for therapy commercialization. Content spans regulatory filings, manufacturing expansions, and intellectual property developments shaping the biostorage industry.
For consistent monitoring of BioLife's market position, bookmark this page or subscribe to Stock Titan's update alerts. All materials maintain strict editorial standards to support informed decision-making in the rapidly evolving cell therapy landscape.
BioLife Solutions (NASDAQ: BLFS) introduced the CryoCase, a new addition to its CellSeal product line at the ISCT Conference in Vancouver. The CryoCase is designed for cell and gene therapy (CGT) primary packaging, aiming to replace cryopreservation bags with a fracture-resistant, rigid construction. It supports both manual and automated, closed-system use.
Available for demonstration at the ISCT event and expected to release to CGT developers in August, the CryoCase offers volume versatility, structural rigidity, and fill/retrieval port designs. It complies with USP 790 and USP 1790 standards and has shown high resistance to leaks and fractures during drop tests.
Early user tests indicated CryoCase may reduce particulates in single-use disposable manufacturing, potentially improving cell viability and recovery. Compatible with BioLife's Signata CT-5 system, CryoCase is expected to lower risks and costs in CGT manufacturing.
BioLife Solutions, Inc. (Nasdaq: BLFS) reported first quarter 2024 financial results with cell processing revenue up 10%, GAAP gross margin at 38%, net loss of $10.2 million, and adjusted EBITDA of $3.6 million. They affirmed revenue guidance for 2024, emphasizing realignment and divestiture of non-core assets to improve financials. Key financial metrics show revenue of $31.7 million, gross margin of 38%, and a net loss of $10.2 million. The company anticipates revenue growth in cell processing and biostorage services platforms.
BioLife Solutions, Inc. (NASDAQ: BLFS) will report its first quarter 2024 financial results on May 9, 2024. The company, a leading supplier of bioproduction tools and services for cell and gene therapies, will host a conference call and webcast to discuss the results and provide a business update. Investors can access the webcast and call details on the BioLife Solutions website.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
